05Ago 2012
oxford_logo

Frederiek van den Bos1,2, Arlene D. Speelman3, Monique Samson1, Marten Munneke4,5, Bastiaan R. Bloem6 and, Harald J. J. Verhaar1

 Conclusion: bone loss in PD is multifactorial. It is clinically important because of the concomitant risk of fractures. Screening for osteoporosis should be considered more often, and therapeutic interventions should be initiated.
Autor: F. van den Bos. Email: f.vandenbos@hagaziekenhuis.nl
04May 2012
Springer

To reveal the mechanism of inflammation-accompanied osteoporosis, mouse CD11b cells and CD4+CD25+ T cells were cocultured. Our results showed that CD11b+ monocytes cocultured with CD4+CD25+ T cells generated significantly less osteoclasts than those cocultured with CD4+CD25− T cells. The levels of MMP-7 and 9 in coculture supernatant were decreased significantly when CD11b+ monocytes and CD4+CD25+ T cells were cocultured comparing to the CD4+CD25− T cell group. These results highlight the role of CD4+CD25+ T cells on rheumatic osteoporosis.

Autor: P. T. Yang, X. H. Meng, Y. Yang, W. G. Xiao
04Mar 2012
Springer

The secreted protein acidic and rich in cysteine (SPARC), also known as osteonectin, plays an important role in osteoblast formation, maturation, and survival.

Summary

The secreted protein acidic and rich in cysteine (SPARC), also known as osteonectin, plays an important role in osteoblast formation, maturation, and survival. Here, we report the effects of recombinant human parathyroid hormone (1-34) [rhPTH (1-34)], a bone formation-stimulating agent, and elcatonin on plasma SPARC levels in patients with osteoporosis. The rhPTH (1-34) treatment significantly increased plasma SPARC levels, and the change of plasma SPARC correlated positively with changes of lumbar bone mineral density (BMD) at L2–L4. These results unveil that SPARC may be a novel marker related to the regulation of bone formation.

Autor: L. Zhang, L. Li, M. Yang, K. Xu, G. Boden, G. Yang